News Center: Providing the Latest Information Sources
Welcome to our news center! Stay updated on real-time developments in Genomics.
Emergency Earthquake Notification
Due to today's strong earthquake, the traffic system is somewhat chaotic. Before it fully restores, there might be delays in our document collection process. If you have urgent issues, please contact your local representative. We apologize for any inconvenience caused.
2024
2024 Qingming Festival long weekend Document Collection and Delivery Announcement
"Dear Customers,
In response to the Qingming Festival long weekend, laboratory business hours will be adjusted as detailed below. Please submit your materials early, and we apologize for any inconvenience caused."
2024
Genomics organizes User Conference that focuses on High-throughput Sequencing and Business Opportunity brought by Big Data, expanding on the application of LTDs certified items, and accelerates toward the high-end NGS market
Genomics entered the Laboratory Developed Tests (LDTs) field over two years ago with internally developed testing technologies, obtaining registration for two items with the TFDA. We continuously add new services to our LDTs certification services, covering areas such as cancer genetics, genetic metabolism, and rare disease gene testing. Leveraging the company's strong foundation in NGS and the excellent relationships established with major medical centers and hospitals nationwide, we aim to seize the laboratory demand and advanced testing opportunities brought by NGS inclusion in national health insurance.
2024
Genomics (4195) Signs Exclusive Sales Agency Contract with Thermo Fisher Scientific
Considering Genomics’ continuous expansion and partnerships in areas such as cell therapy, exosomes, and CDMO, along with plans for new facilities starting this year, there will be a significant demand for laboratory equipment. Therefore, since the second half of 2023, we have actively pursued an exclusive sales agency for certain products of Thermo Fisher Scientific's LPD series in Taiwan. We are delighted to have successfully completed this signing, further deepening our partnership.
2024
Congratulations! Genomics is proud to announce its exclusive distributorship for Thermo Fisher’s Applied Biosystems™ SeqStudio™ Genetic Analyzer in Taiwan's hospital channels.
We extend our heartfelt gratitude to Thermo Fisher for their trust in our capabilities and acknowledgment of our strengths. Genomics boasts the most extensive sequencing service experience in the industry and is Taiwan's largest commercial genomic service provider. Our track record with numerous large-scale projects has significantly contributed to Taiwan's biotech industry.
2024
Case Document Collection and Delivery Announcement for the 2024 Chinese Lunar New Year Vacation
With the Chinese Lunar New Year vacation approaching, we urge you to submit all required documents before the deadline to ensure timely receipt of your reports before the holiday!
2024
Announcement of Office Hour Suspension of Genomics Laboratories for the Holidays in September-October of 2023
In light of the Mid-Autumn Festival and National Day holidays, our laboratory's business hours will be adjusted, resulting in postponed shipping times for certain services. For urgent items or special service requirements, we encourage early submission.
2023
Genomics demonstrate the CDMO Milestone Outcomes at the BIO Asia-Taiwan
The “2023 BIO Asia–Taiwan International Conference and Exhibition” officially opens today (27th). Genomics BioSci & Tech. Co. Ltd., Taiwan’s leading genetic sequencing company (hereafter referred to as “Genomics”, stock code: 4195), announced that the company will demonstrate the milestone outcomes of the company’s transformation progress, showcasing the results of the PIC/S GMP nucleic acid and polypeptide pilot plant at the Expo’s CDMO (Contract Development & Manufacturing Service) Exhibition Area. The company not only has successfully upgraded the nucleic acid synthesis services for scientific research into provision of raw materials for high-grade detection probe kits and nucleic medications, but will also form strategic alliances with partners to jointly develop new products in the future, expanding clinical applications and exploring new international markets. The company seeks to cross into the fields of precision gene therapy and cancer therapy by offering integrated service solutions and maintaining key position in the supply chain of nucleic acid industry.
2023
Expand More
Top
Contact
Contact Us
Contact
Contact Us
Back
Service
overview
